Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“Important update of the ABC trials.
With 6.9y of follow up, adjuvant AC-T had a small RFI benefit over TC, restricted to triple-negative tumors.
No OS benefit by adding anthracyclines, but a major increase in leukemias (7 vs 1) & non-BC deaths (62 vs 34).
https://ascopubs.org/doi/10.1200/JCO.23.01428 “
Source: Paolo Tarantino / X
